+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Fair-Market Value Compensation Rates for Cardiology KOLs - Japan

  • PDF Icon

    Report

  • 21 Pages
  • August 2023
  • Region: Japan
  • Arx Research
  • ID: 5852916
UP TO OFF until Jul 31st 2024

KOL Compensation Japan Cardiology presents fair-market value (FMV) compensation rates for Japanese-based KOLs in Cardiology, by percentiles, with averages, for six (6) activities, for four (4) levels of Thought Leader influences (rare, international, national and local).

Payments made to physicians and thought leaders have been under scrutiny for a few years and companies have been working to adjust their rates to level with industry standards. Adjustments to “market” rates should be done periodically and are best done through 3rd party research, providing a fair and balanced assessment of rates.

These defensible market-based rate data are built directly from industry compensation paid to Healthcare Practitioners (HCPs) and Thought Leaders (KOLs). All KOL FMV rates reports represent fair-market value established using our reliable methodology of collecting data from industry professionals involved in defining compensation levels for exchanges with KOLs worldwide.

Establishing fair-market value compensation rates will:

  • reduce the external perception of inappropriate inducement and limit regulatory and compliance risks.
  • provide an independent reference for negotiations with Thought Leaders (KOLs) and Healthcare Providers (HCPs).
  • refine and support the development of fee schedules that are aligned with market conditions.
  • competitively position the organization and support good business practices.

The data included in each report are an aggregate of collected data and not individual rates. In no event, companies and individuals who provided the data are identified to protect their identity.

KOL Compensation Japan Cardiology

Engage with Thought Leaders early. Recent research shows that less than 25% of pharmaceutical organizations begin working and involving Key Opinion Leaders during or before the clinical phase. Most - 63% - wait during phases 2 and 3 to start exchanging with Thought Leaders. This most likely does not yield the desired results for companies who look to maximize the outcome of any promising product.

Table of Contents

  • Use of the Publisher's Copyrighted Materials
  • Research Methodology
  • Definitions
  • Therapeutic Area
  • Thought Leader Levels
  • Flat Rates
  • Hourly Rates
  • Flat Rates
  • Advisory Board Lead
  • Advisory Board Non-lead
  • Consulting Scientific/Clinical Content
  • Consulting Commercial Content
  • Speaking Scientific/Clinical Content
  • Speaking Commercial Content
  • Other non-specific activities
  • Hourly Rates
  • Advisory Board Lead
  • Advisory Board Non-lead
  • Consulting Scientific/Clinical Content
  • Consulting Commercial Content
  • Speaking Scientific/Clinical Content
  • Speaking Commercial Content
  • Other non-specific activities

Methodology

Analysts use primary and secondary research resources to develop our studies. The quantitative and qualitative data are collected through surveys and interviews conducted with professionals within the area of study. The data presented in our studies are an aggregate of survey and interview input. When possible, the data is presented by country. region or other factor to outline meaningful differences. We protect the identity and privacy of study participants and therefore blind their personal information and the organizations to which they belong - we only present the participation by company size and titles. This enables us to collect unbiased information, provided confidently by participants.

 

Loading
LOADING...